(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of -13.78% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 121.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Ironwood Pharmaceuticals's revenue in 2025 is $308,519,000.On average, 7 Wall Street analysts forecast IRWD's revenue for 2025 to be $45,335,365,683, with the lowest IRWD revenue forecast at $43,220,473,310, and the highest IRWD revenue forecast at $46,936,966,205. On average, 7 Wall Street analysts forecast IRWD's revenue for 2026 to be $42,247,492,872, with the lowest IRWD revenue forecast at $35,943,424,286, and the highest IRWD revenue forecast at $48,660,392,324.
In 2027, IRWD is forecast to generate $29,657,223,455 in revenue, with the lowest revenue forecast at $28,494,195,085 and the highest revenue forecast at $30,529,494,734.